News
The FDA suspends Ixchiq, the only approved chikungunya vaccine, over safety concerns, impacting its availability in the U.S.
According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...
A detail of a packaging of the Ixchiq chikungunya vaccine, in a pharmacy in Saint-Denis, La Réunion, is shown March 21. The ...
HealthDay News — The US Food and Drug Administration (FDA) is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq, in the United States. The move comes after reports ...
U.S. health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of ...
In a U-turn from a decision two weeks ago, the FDA – citing new safety events – said the vaccine is a "danger to health".
Some results have been hidden because they may be inaccessible to you
Show inaccessible results